Medicilon and Suzhou Langrui have reached a strategic collaboration

According to the agreement, Langrui will rely on the KINET AI new drug research and development platform to provide AI technology new drug R&D services to help quickly generate safe and effective FIC/BIC clinical candidate compounds.  At the same time, Medicilon will also rely on a one-stop preclinical biopharmaceutical R&D service platform to provide R&D services including but not limited to drug discovery, pharmaceutical research, and preclinical research.

Suzhou Langrui Bio/h2medical Co., Ltd. is an AI-driven innovative drug research and development company.  At present, the company has brought together AI, CADD, biology, chemistry, software engineering and other multi-disciplinary talents in Suzhou and Shanghai to give full play to the synergistic advantages of domain knowledge and innovative technology.  The technology includes embedding machine learning in target discovery, virtual screening, directional generation of drug molecules, multi-target structure optimization, to create a world-leading biomedical R&D full-chain technology platform, and quickly generate safe and effective FIC/BIC clinical candidate compounds.

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China.  Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  By the end of 2021, Medicilon has provided new drug R&D services to more than 1,460 clients around the world, and participated in the R&D of 221 new drug projects that have been approved for clinical trials.  Medicilon is proud to contribute to human health in the globe.